1. Home
  2. CDT vs CHEK Comparison

CDT vs CHEK Comparison

Compare CDT & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • CHEK
  • Stock Information
  • Founded
  • CDT 2019
  • CHEK 2004
  • Country
  • CDT United States
  • CHEK Israel
  • Employees
  • CDT N/A
  • CHEK N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • CHEK Medical Electronics
  • Sector
  • CDT Health Care
  • CHEK Health Care
  • Exchange
  • CDT Nasdaq
  • CHEK Nasdaq
  • Market Cap
  • CDT 5.2M
  • CHEK 4.5M
  • IPO Year
  • CDT N/A
  • CHEK 2015
  • Fundamental
  • Price
  • CDT $1.93
  • CHEK $0.75
  • Analyst Decision
  • CDT
  • CHEK
  • Analyst Count
  • CDT 0
  • CHEK 0
  • Target Price
  • CDT N/A
  • CHEK N/A
  • AVG Volume (30 Days)
  • CDT 290.9K
  • CHEK 33.7K
  • Earning Date
  • CDT 08-11-2025
  • CHEK 08-14-2025
  • Dividend Yield
  • CDT N/A
  • CHEK N/A
  • EPS Growth
  • CDT N/A
  • CHEK N/A
  • EPS
  • CDT N/A
  • CHEK N/A
  • Revenue
  • CDT N/A
  • CHEK N/A
  • Revenue This Year
  • CDT N/A
  • CHEK N/A
  • Revenue Next Year
  • CDT N/A
  • CHEK N/A
  • P/E Ratio
  • CDT N/A
  • CHEK N/A
  • Revenue Growth
  • CDT N/A
  • CHEK N/A
  • 52 Week Low
  • CDT $1.90
  • CHEK $0.56
  • 52 Week High
  • CDT $622.50
  • CHEK $3.04
  • Technical
  • Relative Strength Index (RSI)
  • CDT 28.61
  • CHEK 43.11
  • Support Level
  • CDT $1.94
  • CHEK $0.73
  • Resistance Level
  • CDT $2.31
  • CHEK $0.80
  • Average True Range (ATR)
  • CDT 0.16
  • CHEK 0.02
  • MACD
  • CDT 0.04
  • CHEK -0.00
  • Stochastic Oscillator
  • CDT 7.02
  • CHEK 21.87

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: